Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
10X Genomics Inc Market Cap
From what 17 stock analysts predict, the share price for 10X Genomics Inc (TXG) might increase by 25.61% in the next year. This is based on a 12-month average estimation for TXG. Price targets go from $14 to $30. The majority of stock analysts believe TXG is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 17 Wall Street analysts have assigned TXG 8 buy ratings, 8 hold ratings, and 1 sell ratings. This means that analysts expect 10X Genomics Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on TXG. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of TXG.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Luke Sergott Barclays | Overweight | $19 | Maintains | Nov 1, 2024 |
| Dan Leonard UBS | Neutral | $20 | Maintains | Oct 30, 2024 |
| Rachel Vatnsdal JP Morgan | Neutral | $14 | Maintains | Oct 30, 2024 |
| Patrick Donnelly Citigroup | Buy | $23 | Maintains | Oct 30, 2024 |
| Matthew Sykes Goldman Sachs | Sell | $14 | Maintains | Oct 30, 2024 |
| Luke Sergott Barclays | Overweight | $21 | Maintains | Oct 15, 2024 |
| Mason Carrico Stephens & Co. | Overweight | $30 | Reiterates | Oct 10, 2024 |
| Kyle Mikson Canaccord Genuity | Buy | $20 | Maintains | Oct 10, 2024 |
| Mason Carrico Stephens & Co. | Overweight | $30 | Reiterates | Sep 4, 2024 |
| Mike Kratky Leerink Partners | Outperform | $35 | Initiates | Sep 3, 2024 |
| Tejas Savant Morgan Stanley | Overweight | $46 | Maintains | Aug 13, 2024 |
| Dan Leonard UBS | Neutral | $25 | Maintains | Aug 13, 2024 |
| Kyle Mikson Canaccord Genuity | Buy | $32 | Maintains | Jul 23, 2024 |
| Tycho Peterson Jefferies | Buy | $24 | Upgrade | Jul 22, 2024 |
| Derik De Bruin B of A Securities | Neutral | $25 | Maintains | Jul 18, 2024 |
| Rachel Vatnsdal JP Morgan | Neutral | $20 | Downgrade | Jul 18, 2024 |
| Daniel Arias Stifel | Buy | $25 | Maintains | Jul 16, 2024 |
| Justin Bowers Deutsche Bank | Hold | $25 | Downgrade | Jul 10, 2024 |
| Matthew Sykes Goldman Sachs | Sell | $16 | Maintains | Jul 9, 2024 |
| Luke Sergott Barclays | Overweight | $24 | Maintains | Jun 28, 2024 |
When did it IPO
2019
Staff Count
1,259
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Dr. Serge Saxonov Ph.D.
Market Cap
$1.96B
In 2023, TXG generated $618.7M in revenue, which was a increase of 19.81% from the previous year. This can be seen as a signal that TXG's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - 10x Genomics (Nasdaq: TXG) will participate in a fireside chat at the Wolfe Research 2024 Healthcare Conference on November 19 at 1:00 p.m.
Why It Matters - Management participation in a prominent healthcare conference signals potential growth opportunities and investor interest, which can impact stock performance for 10x Genomics.
Wed, 30 Oct 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - 10x Genomics, Inc. (TXG) reported a loss for the third quarter.
Why It Matters - 10x Genomics' reported loss may indicate financial instability, affecting stock performance and investor confidence, potentially leading to a reevaluation of growth prospects.
Thu, 31 Oct 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Cure51 will analyze over 1,000 tumor samples from exceptional cancer survivors using 10x Genomics' Visium HD technology to explore new therapeutic approaches.
Why It Matters - Cure51's partnership with 10x Genomics to analyze tumor samples may lead to breakthrough cancer therapies, potentially increasing the value of both companies and attracting investor interest.
Tue, 29 Oct 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - 10x Genomics, Inc. (NASDAQ:TXG) will host its Q3 2024 Earnings Conference Call on October 29, 2024, at 4:30 PM ET, featuring key executives and multiple financial analysts.
Why It Matters - The earnings call provides insights into 10x Genomics' financial performance and strategic direction, influencing investor sentiment and stock valuation based on growth potential and market positioning.
Tue, 29 Oct 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - 10x Genomics, Inc. (Nasdaq: TXG) announced its third-quarter financial results for the period ending September 30, 2024.
Why It Matters - 10x Genomics' Q3 financial results can influence stock performance and investor sentiment, impacting valuation and future growth expectations in the biotech sector.
Mon, 28 Oct 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - 10x Genomics expects a revenue decline for Q3, driven by lower instrument sales, though this may be partially offset by growth in consumable sales.
Why It Matters - Declining revenues signal potential challenges for 10x Genomics, affecting investor confidence. Growth in consumable sales may mitigate losses, but overall performance could impact stock valuation.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
